Huda S. Salman

Randomized Phase II Trial of Embolization Therapy Versus Chemoembolization Therapy in Previously Treated Patients with Colorectal Carcinoma Metastatic to the Liver

Huda S. Salman, Jacov Cynamon, Marci Jagust et al. · Clinical Colorectal Cancer · 2002 · 60 citations

Medicine, Oncology, Chemotherapy +15

Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL).

Jeffrey A. Jones, Tadeusz Robak, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2015 · 23 citations

Medicine, Pharmacology, Pharmacotherapy +15

Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Jacob D. Soumerai, John M. Pagel, Deepa Jagadeesh et al. · Journal of Clinical Oncology · 2018 · 18 citations

Medicine, Pharmacology, Pharmacotherapy +16

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

Andrew D. Zelenetz, Jacob D. Soumerai, Deepa Jagadeesh et al. · Blood · 2018 · 14 citations

Pharmacy, Pharmacology, Pharmacotherapy +8

Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL).

Andrew D. Zelenetz, Deepa Jagadeesh, Nishitha Reddy et al. · Journal of Clinical Oncology · 2019 · 12 citations

Medicine, Pharmacology, Pharmacotherapy +16